Search

Displaying results 5781 - 5790 of 8171 in total
  1. Drug

    FT516

    go.drugbank.com/drugs/DB15732
    Investigational

    FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). … This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation.

  2. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells.

  3. Drug

    Bafilomycin A1

    go.drugbank.com/drugs/DB06733
    Experimental

    This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.

  4. Drug

    Ralmitaront

    go.drugbank.com/drugs/DB19128
    Investigational

    Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or

  5. Drug

    Rexlemestrocel-L

    go.drugbank.com/drugs/DB17606
    Investigational

    Rexlemestrocel-L is an investigational human bone marrow-derived allogeneic mesenchymal precursor cell (MPC) product.

  6. Drug

    CX-2009

    go.drugbank.com/drugs/DB16090
    Investigational

    CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).

  7. Drug

    Boldenone

    go.drugbank.com/drugs/DB01541
    ExperimentalIllicitVet approved

    Boldenone is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.

  8. Drug

    AUTO3

    go.drugbank.com/drugs/DB17364
    Investigational

    It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.

  9. Drug

    KITE-585

    go.drugbank.com/drugs/DB17409
    Investigational

    KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.

  10. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]